•Ollin raises $330M to advance OLN324 in phase 3 studies for DME and wet AMD•Study identifies stroke risks following ischemic ocular events•Study suggests ocular history may raise risk for recurrent shingles•Genentech's sBLA for subcutaneous TED therapy receives FDA priority review•Harrow relaunches biosimilar Byooviz in the US •Ollin raises $330M to advance OLN324 in phase 3 studies for DME and wet AMD•Study identifies stroke risks following ischemic ocular events•Study suggests ocular history may raise risk for recurrent shingles•Genentech's sBLA for subcutaneous TED therapy receives FDA priority review•Harrow relaunches biosimilar Byooviz in the US
HEADLINES
![[object Object]](/_next/image/?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F51cpf7jm%2Fproduction%2Fa59f0611b99f404a5cf253958bf4abff5320346c-1200x628.png%3Fw%3D2400%26q%3D100%26fit%3Dfill%26auto%3Dformat&w=3840&q=75)
FEATURED
Bruno Vision Care’s FDA-cleared Deseyne lens improved intermediate and near vision while maintaining good distance vision in adults with presbyopia.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
